Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis - PubMed (original) (raw)
. 2004 Jul;50(7):2327-37.
doi: 10.1002/art.20384.
Affiliations
- PMID: 15248234
- DOI: 10.1002/art.20384
Free article
Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis
Petra Herrak et al. Arthritis Rheum. 2004 Jul.
Free article
Abstract
Objective: Increased osteoclast activity is a key factor in bone loss in rheumatoid arthritis (RA). This suggests that osteoclast-targeted therapies could effectively prevent skeletal damage in patients with RA. Zoledronic acid (ZA) is one of the most potent agents for blocking osteoclast function. We therefore investigated whether ZA can inhibit the bone loss associated with chronic inflammatory conditions.
Methods: Human tumor necrosis factor (TNF)-transgenic (hTNFtg) mice, which develop severe destructive arthritis as well as osteoporosis, were treated with phosphate buffered saline, single or repeated doses of ZA, calcitonin, or anti-TNF, at the onset of arthritis.
Results: Synovial inflammation was not affected by ZA. In contrast, bone erosion was retarded by a single dose of ZA (-60%) and was almost completely blocked by repeated administration of ZA (-95%). Cartilage damage was partly inhibited, and synovial osteoclast counts were significantly reduced with ZA treatment. Systemic bone mass dramatically increased in hTNFtg mice after administration of ZA, which was attributable to an increase in trabecular number and connectivity. In addition, bone resorption parameters were significantly lowered after administration of ZA. Calcitonin had no effect on synovial inflammation, bone erosion, cartilage damage, or systemic bone mass. Anti-TNF entirely blocked synovial inflammation, bone erosion, synovial osteoclast formation, and cartilage damage but had only minor effects on systemic bone mass.
Conclusion: ZA appears to be an effective tool for protecting bone from arthritic damage. In addition to their role in antiinflammatory drug therapy, modern bisphosphonates are promising candidates for maintaining joint integrity and reversing systemic bone loss in patients with arthritis.
Comment in
- Bisphosphonates: environmental protection for the joint?
Goldring SR, Gravallese EM. Goldring SR, et al. Arthritis Rheum. 2004 Jul;50(7):2044-7. doi: 10.1002/art.20383. Arthritis Rheum. 2004. PMID: 15248201 Review. No abstract available.
Similar articles
- Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis.
Sims NA, Green JR, Glatt M, Schlict S, Martin TJ, Gillespie MT, Romas E. Sims NA, et al. Arthritis Rheum. 2004 Jul;50(7):2338-46. doi: 10.1002/art.20382. Arthritis Rheum. 2004. PMID: 15248235 - Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, Dunstan C, Kollias G, Steiner G, Smolen J, Schett G. Zwerina J, et al. Arthritis Rheum. 2004 Jan;50(1):277-90. doi: 10.1002/art.11487. Arthritis Rheum. 2004. PMID: 14730626 - Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
Schett G, Redlich K, Hayer S, Zwerina J, Bolon B, Dunstan C, Görtz B, Schulz A, Bergmeister H, Kollias G, Steiner G, Smolen JS. Schett G, et al. Arthritis Rheum. 2003 Jul;48(7):2042-51. doi: 10.1002/art.11150. Arthritis Rheum. 2003. PMID: 12847699 - Bone and joint destruction in rheumatoid arthritis: what is really happening?
Goldring SR. Goldring SR. J Rheumatol Suppl. 2002 Sep;65:44-8. J Rheumatol Suppl. 2002. PMID: 12236623 Review. - The role of interleukin-1 in bone resorption in rheumatoid arthritis.
Strand V, Kavanaugh AF. Strand V, et al. Rheumatology (Oxford). 2004 Jun;43 Suppl 3:iii10-iii16. doi: 10.1093/rheumatology/keh202. Rheumatology (Oxford). 2004. PMID: 15150427 Review.
Cited by
- Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection.
Jones D, Glimcher LH, Aliprantis AO. Jones D, et al. J Clin Invest. 2011 Jul;121(7):2534-42. doi: 10.1172/JCI46262. Epub 2011 Jul 1. J Clin Invest. 2011. PMID: 21737885 Free PMC article. - Clinical immunity in bone and joints.
Tanaka Y. Tanaka Y. J Bone Miner Metab. 2019 Jan;37(1):2-8. doi: 10.1007/s00774-018-0965-5. Epub 2018 Oct 15. J Bone Miner Metab. 2019. PMID: 30324535 Review. - The phosphoinositide 3-kinase isoform PI3Kβ regulates osteoclast-mediated bone resorption in humans and mice.
Győri D, Csete D, Benkő S, Kulkarni S, Mandl P, Dobó-Nagy C, Vanhaesebroeck B, Stephens L, Hawkins PT, Mócsai A. Győri D, et al. Arthritis Rheumatol. 2014 Aug;66(8):2210-21. doi: 10.1002/art.38660. Arthritis Rheumatol. 2014. PMID: 24719382 Free PMC article. - Cells of the synovium in rheumatoid arthritis. Osteoclasts.
Schett G. Schett G. Arthritis Res Ther. 2007;9(1):203. doi: 10.1186/ar2110. Arthritis Res Ther. 2007. PMID: 17316459 Free PMC article. Review. - Pathological role of osteoclast costimulation in arthritis-induced bone loss.
Ochi S, Shinohara M, Sato K, Gober HJ, Koga T, Kodama T, Takai T, Miyasaka N, Takayanagi H. Ochi S, et al. Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11394-9. doi: 10.1073/pnas.0701971104. Epub 2007 Jun 25. Proc Natl Acad Sci U S A. 2007. PMID: 17592115 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical